Regeneron Pharmaceuticals (REGN)
NASDAQ • Healthcare
January 21, 2026 at 19:17 UTC
Name
CEO
Website
Industry
Year Founded
Employees
Regeneron Pharmaceuticals is a biotechnology company that discovers and develops medicines built on antibody and genetic insights. Its labs translate biology into candidates, clinical teams test those candidates with rigorous endpoints, and manufacturing scales successful therapies for reliable supply. The operating model favors platforms that can be reapplied across conditions, which speeds learning without cutting corners. Medical affairs focuses on clear labeling and appropriate use, and post-approval work tracks outcomes so guidance can improve. Collaborations with research centers and peers widen the scientific base while keeping control of quality and data. Within healthcare, Regeneron’s role is to move promising science into practical treatment that fits the routines of real clinics.
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Regeneron Pharmaceuticals's Technical Indicators Summary
REGN’s technical profile reflects a neutral stance as the average directional index signals moderate trend strength without clear momentum, supported by a balanced RSI near the midrange and mixed momentum readings. The current price sits below most short- and medium-term moving averages, which suggest some selling pressure, yet remains above key long-term averages, indicating underlying support. Volatility measures are steady, while volume-based indicators point to mild selling interest. Overall, the combination of subdued momentum, moderate trend strength, and mixed moving average alignments results in a neutral technical outlook for REGN at this time. The technical takeaway is that REGN currently exhibits a cautious balance between bullish and bearish forces.
| Indicator | Value |
|---|---|
RSI (14) | 41.41 |
Stochastic %K (14, 3, 3) | 8.68 |
CCI (20) | -169.15 |
WPR (14) | -93.02 |
Momentum (10) | -43.27 |
MFI | 37.17 |
MACD Level (12, 26) | 4.29 |
Bollinger Bands | $733.80 - $812.01 |
ATR (14) | $21.10 (2.88%) |
ADX (14) | 23.50 |
OBV | -1,181,300 |
Simple Moving Averages | $610.60 - $772.91(5 indicators) |
Exponential Moving Averages | $654.99 - $762.85(5 indicators) |
Get premium market insights delivered directly to your inbox.
The new session started on a slightly positive note as REGN opened 0.399% higher at 736.71 versus 733.78. At the open, derivatives traders in REGN are heavily hedged, with a put/call ratio of 1.61. Regeneron opens slightly higher amid institutional buying and ongoing positive earnings momentum.
Price Change
from $733.78 close
+$12.63
Trading Volume
Below avg (1.0M)
113.5K
vs S&P 500 Today
Strong Outperformance
+11.77%
52-Week Position
Upper range
78.3%
Updated: January 21, 2026 at 15:35 UTC
2025 Valuation Insights: Spotify, Aker BP, and Key Growth Stocks
December 7, 2025